Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma

NCT00484601 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Low accrual.

Conditions

Refractory Nasopharyngeal Carcinoma

Interventions

DRUG: Ifosfamide
DRUG: Doxorubicin

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins